CNS Tumors (GBM & Primary CNS Lymphoma)

CNS tumors encompass glioblastoma (GBM) and primary CNS lymphoma (PCNSL) — two distinct but often co-managed entities in neuro-oncology. Glioblastoma, the most common malignant primary brain tumor in adults, is treated with the Stupp protocol (concurrent temozolomide + 60 Gy radiation followed by adjuvant temozolomide); MGMT promoter methylation predicts temozolomide benefit. Primary CNS lymphoma is an aggressive ABC-subtype DLBCL confined to the brain, spinal cord, or eyes, treated with high-dose methotrexate–based induction (MATRix or R-MPV) and consolidation with autologous SCT or whole-brain radiation.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for CNS Tumors (GBM & Primary CNS Lymphoma)

• Temozolomide (Temodar) — Alkylating Agent
• Bevacizumab (Avastin) — Monoclonal Antibody
• Lomustine (Gleostine) — Alkylating Agent
• Carmustine (BiCNU) — Alkylating Agent
• Methotrexate (Trexall) — Antimetabolite
• Cytarabine (Cytosar-U) — Antimetabolite
• Thiotepa (Tepadina) — Alkylating Agent
• Rituximab (Rituxan) — Monoclonal Antibody
• Ibrutinib (Imbruvica) — Tyrosine Kinase Inhibitor